Search research articles
Contact Us
Filters
Showing results (41-50 of 60) with videos related to
Page
of 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
January 30, 2009
Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer
James W Denham, Mahesh Kumar, Paul S Gleeson, et al.
European Urology
|
September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
Shankar Siva, Mathias Bressel, Declan G Murphy, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer
James W Denham, Chantelle Wilcox, David S Lamb, et al.
The Lancet. Oncology
|
November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial
James W Denham, Chantelle Wilcox, David Joseph, et al.
Medical Physics
|
November 10, 2022
The dosimetric error due to uncorrected tumor rotation during real-time adaptive prostate stereotactic body radiation therapy
Chandrima Sengupta, Simon Skouboe, Thomas Ravkilde, et al.
The Lancet. Oncology
|
December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
James W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology
|
August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial
James W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology
|
November 1, 2005
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
James W Denham, Allison Steigler, David S Lamb, et al.
The Lancet. Oncology
|
May 9, 2016
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Gillian M Duchesne, Henry H Woo, Julie K Bassett, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 24, 2020
Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial
Emily A Hewson, Doan T Nguyen, Ricky O'Brien, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 60) with videos related to
Sort By:
Page
of 6
International Journal of Radiation Oncology, Biology, Physics
|
January 30, 2009
Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer
James W Denham, Mahesh Kumar, Paul S Gleeson, et al.
European Urology
|
September 20, 2018
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial
Shankar Siva, Mathias Bressel, Declan G Murphy, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer
James W Denham, Chantelle Wilcox, David S Lamb, et al.
The Lancet. Oncology
|
November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial
James W Denham, Chantelle Wilcox, David Joseph, et al.
Medical Physics
|
November 10, 2022
The dosimetric error due to uncorrected tumor rotation during real-time adaptive prostate stereotactic body radiation therapy
Chandrima Sengupta, Simon Skouboe, Thomas Ravkilde, et al.
The Lancet. Oncology
|
December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
James W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology
|
August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial
James W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology
|
November 1, 2005
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
James W Denham, Allison Steigler, David S Lamb, et al.
The Lancet. Oncology
|
May 9, 2016
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Gillian M Duchesne, Henry H Woo, Julie K Bassett, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 24, 2020
Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial
Emily A Hewson, Doan T Nguyen, Ricky O'Brien, et al.
Page
of 6